Opella Egypt leads with purpose at Africa Health ExCon
Egypt – Opella Egypt participated as a Gold Sponsor at Africa Health ExCon 2025, co-hosted by Africa Centres for Disease Control and Prevention (Africa CDC), Africa's leading healthcare event. The conference welcomed over 60,000 attendees from 150+ countries, held under the patronage of President Abdel Fattah El-Sisi.
'Towards Sustainable Healthcare' session, held by Opella on June 25, focused on Opella's sustainability, B Corp certification and self-care vision. At the heart of the session was a panel on e-Labelling, a joint ambition by Opella and the Egyptian Drug Authority (EDA) to cut waste and expand access to reliable health information. The takeaway was simple: Digital, eco-friendly tools aren't optional. They're essential for a smarter, more sustainable future.
Opella leaders, experts from the World Health Organization (WHO), the EDA, South Africa's regulatory bodies, and the Global Self-Care Federation (GSCF) contributed valuable insights. The message was clear: Long-term impact starts with informed choices, stronger health literacy, and is bolstered by collaboration. Opella achieved a new milestone on its journey to deliver responsible self-care for people and planet. Certified by B Lab, B Corp recognizes companies that meet rigorous standards of social and environmental performance, transparency, and accountability.
Marissa Saretsky, Chief Sustainability Officer:
' We are proud to be the first global consumer healthcare company to achieve B Corp Certification, reflecting our commitment to sustainability and accountability. Our strategy towards a healthier planet and society focuses on decarbonizing our operations and value chain, embedding circularity, driving health literacy and supporting surrounding communities through NGO partnerships. We look forward to working with all partners across the sector to make sustainable self-care second nature. '
Dr Josephine Fubara, Chief Science Officer:
' e-Labeling puts more power in the hands of consumers. It empowers consumers by making self-care easier, more accessible, and sustainable—while simplifying healthcare for everyone. To realize its full potential, we need early, open collaboration across regulators, industry, healthcare professionals, and patients. '
Feirouz Ellouze, General Manager (AMET):
' Opella's presence at the conference highlights our commitment to sustainable healthcare systems. We are a dedicated global self-care leader, ready to meet the health needs of consumers. Our independence allows us to innovate faster and stay focused on our mission: making self-care as simple as it should be - for everyone. '
The EDA has been leading a multi-phase e-Labelling shift to modernize medicine information and boost sustainability. Launched in 2022, The initiative, launched in 2022, replaces paper leaflets with QR-linked digital formats, starting with hospital-use products. Now in its second phase, it supports health literacy, cuts paper waste, and sets the stage for full digital integration using global standards.
By digitizing the 60 million leaflets provided annually by Opella Egypt alone, we could save 300 tonnes of carbon emissions and protect 5,400 trees. Recognizing the significance of collaboration and active participation among various stakeholders, Opella is committed to supporting initiatives that facilitate this transition and drive sustainable change.
About Opella.
Opella is the self-care challenger with third-largest portfolio in the Over-The-Counter (OTC) & Vitamins, Minerals & Supplements (VMS) market globally. Our mission is to bring health in people's hands by making self-care as simple as it should be. For half a billion consumers worldwide – and counting.
At the core of this mission are our brands worldwide, our 11,000-strong global team, our 13 best-in-class manufacturing sites and 4 specialized science and innovation development centers. Headquartered in France, Opella is the proud maker of many brands worldwide, including Telfast, Doliprane, Bronchicum, Enterogermina, Maalox, Nasacort, Maxilase, Bisolvon and Buscopan, B Corp certified, we are active players in the journey towards healthier people and planet.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The National
20 hours ago
- The National
A cancer crisis is inevitable. What can we do about it?
The number of cancer patients is set to rise dramatically throughout the entire Gulf region. This is simply because of changes in the age of its population. Cancer can, of course, occur at any age but it predominantly occurs in older people. In the UK, 25 per cent of the population is now over 60 compared to only 3.6 per cent in the UAE. The number of new cancer patients in this region per million people is currently less than half that in Europe. But this is set to change rapidly with a much more European age pattern coming to all GCC countries. The risk factors for cancer due to age are already locked-in, so a health crisis is inevitable. There will be a significant rise in both incidence (the number of new cases) and prevalence (the number of patients living with cancer). The World Health Organisation predicts a more than doubling of both in the GCC region by 2050. The 'big four' cancers are those arising in breast, colon, lung and prostate, which make up 65 per cent of diagnoses. Each cancer has its own age profile and causation. As breast cancer starts rising in women in their forties, it is unsurprising that we are already seeing a huge increase. The other types will surely follow in the next decade. But a real puzzle is emerging. Over the past 20 years, we have seen a dramatic increase of certain cancers in the 30-50 age group globally. This trend started in the 1990s, so has nothing to do with Covid-19 or its vaccines. Lymphoma, melanoma, head and neck as well as the big four cancers are all involved. What is going on and what can we do about it? We know that age is the biggest risk factor and we just cannot stop the clock. But changing lifestyles are definitely involved too. The interplay of diet, exercise and obesity can alter the hormonal balance in the body. How we work, play and relax now is different from the past. Only three generations ago, the Gulf was a land of nomadic tribesmen with a healthy lifestyle. Subsequent generations now sit in smart high-rise offices, often with sedentary lifestyles and a diet heavy with processed food. But why is this increasing the risk of cancer? Our lifestyle contributes to the composition of the microbiome – the bugs that colonise our intestines breaking down potential carcinogens and toxins. Powerful data-mining artificial intelligence programmes are being used to study the huge number of variables involved. Within five years, it is likely we will understand more clearly the factors causing defects in cell growth control that allow rogue cells to emerge. These become the enemy within – the cancer. Greater understanding will allow specific tailored cancer prevention advice to individuals. Prevention and screening messages are always far more powerful if individualised. Risk-based screening for common cancers will be revolutionised by multi-cancer early detection tests, or MCEDs. These pick up abnormal DNA fragments released by tiny early cancers which circulate in the blood. Although there are several on the market, they produce too high a false positive rate to be used on everyone. They can make the worried well even more worried. Eventually, a reliable, self-administered finger prick sample will be enough to diagnose cancer accurately, but we're just not there yet. Understanding the reasons that cancer arises at a molecular level will lead to both better prevention and more effective treatment strategies. But oncologists need to steer a delicate path between hope, hype and reality for this increasingly common disease Technology will allow us to diagnose cancer in its very early stages where outcomes are best. The Gulf is well provided with increasingly sensitive diagnostic scanners, both MRI and CT. And molecular analysis of biopsies from cancers will provide far more personalised individual drug and radiation combinations. The future physicians' laptop will not only choose the optimal therapy but also predict probable unpleasant side effects. AI will be used extensively to understand individual interactions to treatments – both good and bad allowing perfect personalisation. The Gulf has many excellent cancer treatment facilities. But there are few effective networks allowing the combination of international expertise bringing multi-disciplinary opinions for patients and yet delivering care close to their homes currently in place. Treating cancer effectively is no quick fix, often taking several months of frequent hospital visits for radiotherapy and chemotherapy. The medical tourism model used for elective surgery is not feasible. The increasing cost of optimal cancer care is driving government health bodies globally to reduce the wide inconsistencies in treatment protocols. Networked care from a mixed economy of public and private providers is very much the future. It allows the development of a financially sustainable model adapted to a country's overall wealth. Increasing financial investment into an individuals' cancer care obviously increases the benefit to the patient. But there is a limit – a therapeutic plateau – where further spending brings no benefit for the patient. Poorer countries such as those of middle Africa operate well below it; most of Europe and Asia is comfortably at its beginning but the US is far along it, spending vast sums of money for no gain in the last few months of a patients' life. Networked care is the solution to providing the best individual treatment and yet minimising its toxicity both for the patient and financially for the payor. Coupling the intellectual power of a large central university hospital with skilled technical care close to home is what families want. Currently we cure over 90 per cent of patients with early-stage cancer. When the disease has spread outside its organ of origin, this figure drops dramatically. So, the emphasis has to be on streamlining the diagnostic phase and fast-tracking treatment. The current emphasis is very much on maintaining the best quality of life both during and after therapy. We are now far more honest with our patients and try to manage their expectations with frankness. Breakthroughs appear in the media regularly driven by commercial interests from biotech and pharma companies and their investors. Their hyped-up message can often raise false hope. Public education and better screening lead to earlier diagnosis and better outcomes. Understanding the reasons that cancer arises at a molecular level will lead to both better prevention and more effective treatment strategies. But oncologists need to steer a delicate path between hope, hype and reality for this increasingly common disease.
Zawya
21 hours ago
- Zawya
Eritrea: Voluntary blood donation in Central Region
Government workers from various institutions in the Central Region voluntarily donated 70 units of blood on 25 and 26 June in support of the National Blood Transfusion Service. The program was carried out with the participation of members from the Ministry of Labor and Social Welfare Central Office, Hidri Distribution Company, and the Electricity Corporation of Eritrea. The participants expressed satisfaction in contributing to the life-saving cause, noting the importance of donating renewable blood. Nurse Sara Michael, a member of the center, emphasized that voluntary blood donation is a key factor in enriching the blood supply of the National Blood Transfusion Service. She urged the public to raise awareness about the importance of voluntary blood donation in saving lives. Distributed by APO Group on behalf of Ministry of Information, Eritrea.
Zawya
a day ago
- Zawya
South Africa's Biovac to make, distribute pneumonia vaccine across Africa
Cape Town-based biopharmaceutical company Biovac has signed a transfer agreement with Biological E in India to manufacture and distribute a pneumonia vaccine across Africa. Biological E's PCV14 – a 14-valent pneumococcal conjugate vaccine, having broad serotype coverage – was found to be non-inferior to Prevenar 13 for all shared serotypes in the pivotal phase-three randomised, active control trial. Biological E's PCV14 vaccine is already licensed in India and is currently undergoing World Health Organisation (WHO) prequalification with the aim being to make the vaccine available to Unicef and Gavi markets soon thereafter. In parallel, a technology transfer is being initiated with Biovac that is anticipated to take three years including regulatory approval. Pneumococcal infection, which the vaccine protects against, is a cause of significant disease, being a leading cause of pneumonia, bacterial meningitis, and sepsis. WHO estimated that in 2005, pneumococcal infections were responsible for the death of 1.6 million children worldwide and while this has reduced significantly over time, newer and better vaccines are still needed. Dr Morena Makhoana, Biovac CEO, states: 'Biovac is on a steady journey of ensuring that it expands its footprint beyond South Africa. We do so by carefully selecting our partners and the type of products that meet our customers' needs.
